Physician profile
Craig T Wright
NPI 1144544719
$4,262.71
in general payments reported to CMS, 2019-2025
36 companies · $40.35 in 2025
The $40.35 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,619 · 2020: $1,213 · 2021: $1,025 · 2022: $307 · 2023: $43.13 · 2024: $15.73 · 2025: $40.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $99.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $99.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $584.46 | 2019-2022 | |
| Novo Nordisk INC | $388.79 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $348.58 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.24 | 2019-2022 | |
| Lilly USA, LLC | $312.26 | 2019-2025 | Zepbound |
| Pfizer INC. | $295.58 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $269.33 | 2019-2022 | |
| Allergan, INC. | $258.63 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $222.88 | 2019-2021 | |
| Amgen INC. | $147.74 | 2019-2022 | |
| Abbvie INC. | $126.08 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $113.18 | 2019-2020 | |
| Glaxosmithkline, LLC. | $91.36 | 2019 | |
| Jazz Pharmaceuticals INC. | $91.09 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $77.77 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $63.12 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $54.65 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $45.43 | 2020-2021 | |
| Abbott Laboratories | $40.25 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Daiichi Sankyo INC. | $38.19 | 2020 | |
| Depuy Synthes Sales INC. | $38.19 | 2021-2022 | |
| Boston Scientific Corporation | $36.37 | 2022 | |
| Gilead Sciences, INC. | $30.24 | 2019 | |
| Dexcom, INC. | $26.02 | 2025 | Dexcom G6 Transmitter |
| Covidien LP | $24.60 | 2019 | |
| Ethicon US, LLC | $24.04 | 2021 | |
| Shire North American Group INC | $20.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.91 | 2020 | |
| Amarin Pharma, INC. | $19.48 | 2022 | |
| Eisai INC. | $18.90 | 2022 | |
| Heartflow, INC. | $18.61 | 2023 | Ffrct |
| Dermira, INC. | $17.88 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.55 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.15 | 2019 | |
| Antares Pharma, INC. | $12.44 | 2019 | |
| Hologic Sales and Service, LLC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.